Literature DB >> 14657088

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.

Andreas H Groll1, Hedwig Kolve, Karoline Ehlert, Michael Paulussen, Josef Vormoor.   

Abstract

Voriconazole is a novel antifungal triazole that undergoes extensive oxidative metabolization involving several CYP450 isoenzymes. We report the case of a 14-year-old patient who received voriconazole concomitant with ciclosporin A as secondary antifungal prophylaxis after bone marrow transplantation. Temporary discontinuation of voriconazole due to worsening liver function tests (LFTs) resulted in a sudden drop of ciclosporin A trough levels in blood. Ciclosporin A trough levels returned to baseline following normalization of LFTs and re-institution of voriconazole. This report emphasizes the need for careful monitoring and dose adjustments of ciclosporin A in patients receiving concomitant voriconazole, and in whom voriconazole is discontinued in order to prevent subtherapeutic ciclosporin A levels with the potential consequence of graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657088     DOI: 10.1093/jac/dkh022

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Shelly L Carter; Thomas J Walsh; Joanne Kurtzberg; Trudy N Small; Lindsey R Baden; Iris D Gersten; Adam M Mendizabal; Helen L Leather; Dennis L Confer; Richard T Maziarz; Edward A Stadtmauer; Javier Bolaños-Meade; Janice Brown; John F Dipersio; Michael Boeckh; Kieren A Marr
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

2.  Effect of posaconazole on the concentration of intravenous and oral cyclosporine in patients undergoing hematopoietic stem cell transplantation.

Authors:  Li-E Zhu; Hui-Ping Huang; Yi-Peng Cai; Yan Wang; Bao-Hua Xu; Mao-Bai Liu; Xue-Mei Wu
Journal:  Eur J Clin Pharmacol       Date:  2022-08-31       Impact factor: 3.064

3.  The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.

Authors:  Hugo Vanden Bossche; Jannie Ausma; Hilde Bohets; Karen Vermuyten; Gustaaf Willemsens; Patrick Marichal; Lieven Meerpoel; Frank Odds; Marcel Borgers
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.